QR kód

Long-Term Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthritis: Final Results from the BALANCE-EXTEND Open-Label Extension Study

Abstract Introduction Upadacitinib (UPA) is an oral, selective Janus kinase inhibitor that has demonstrated favorable efficacy with an acceptable safety profile across a global, phase 3 program in rheumatoid arthritis (RA). This phase 2 open-label extension investigated the efficacy and safety of UP...

Celý popis

Uloženo v:
Hlavní autoři: Alan Kivitz, Alvin F. Wells, Juan I. Vargas, Herbert S. B. Baraf, Maureen Rischmueller, Justin Klaff, Nasser Khan, Yihan Li, Kyle Carter, Alan Friedman, Patrick Durez
Médium: Artigo
Jazyk:Inglês
Vydáno: Adis, Springer Healthcare 2023-05-01
Edice:Rheumatology and Therapy
Témata:
Extension
Janus kinase inhibitor
Phase 3
Rheumatoid arthritis
Treatment
Upadacitinib
On-line přístup:https://doi.org/10.1007/s40744-023-00557-x
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky